Skip to main content
Premium Trial:

Request an Annual Quote

InteRNA, Radboud University Collaborate on miRNA Rx for Prostate Cancer

Premium

InteRNA Technologies and Radboud University Nijmegen Medical Centre said this week that they have agreed to collaborate on the development of microRNA-based therapeutics for prostate cancer.

Under the research arrangement, InteRNA's lentiviral-based miRNA over-expression library "will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer," the partners said.

Additional terms were not disclosed.